Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission (NCT02927262) | Astellas Pharma Global Development, Inc. | 2017-01-10 |
Track Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation automatically
Every clearance here is in the API, with alerts when new ones post.